Mindray announced a new integration as part of its cooperative agreement with Edwards Lifesciences, a provider of medical innovations for structural heart disease and critical care monitoring.

The new solution integrates Mindray’s BeneVision N-Series patient monitoring system with the Edwards FloTrac sensor for hemodynamic monitoring in the North American market.

The continuous monitoring of pressure and flow parameters is essential for managing hemodynamically unstable patients to guide appropriate treatment. The BeneVision N-Series Patient Monitors combine the advanced hemodynamic parameters of the FloTrac sensor with other vital sign parameters, giving critical care providers greater insights into patients’ physiological status.

“At Mindray, we are continuously searching for new ways to improve patient outcomes by providing the most innovative technology on the market,” said Wayne Quinn, president, Mindray North America. “Collaborating with industry-leading companies such as Edwards Lifesciences enables us to deliver a comprehensive monitoring solution that gives clinicians access to trusted, evidence-based technology to meet the acute care needs of their hospital and enhance patient safety.”

The FloTrac sensor technology expands the N-Series capability to monitor patients’ hemodynamic condition. It helps clinicians act more proactively to prevent patient deterioration and apply individualized fluid management for patients in surgical and acute care settings.